Dexketoprofen-induced antinociception in animal models of acute pain: Synergy with morphine and paracetamol

Hugo F. Miranda, Margarita M. Puig, Christian Dursteler, Juan Carlos Prieto, Gianni Pinardi

Resultado de la investigación: Article

35 Citas (Scopus)

Resumen

The antinociceptive activity of dexketoprofen was studied in mice using the acetic acid writhing test (acute tonic pain), the tail flick test (acute phasic pain) and the formalin assay (inflammatory pain). Isobolographic analysis was used to study the antinociceptive interactions between morphine and paracetamol co-administered with dexketoprofen. In the writhing test, the intraperitoneal administration of dexketoprofen or ketoprofen resulted in parallel dose-response curves with equal efficacy, but higher relative potency for dexketoprofen. In the tail flick test, the curves were parallel with similar efficacy and potency. The administration of morphine or paracetamol in both tests resulted in dose-response curves not parallel with that of dexketoprofen, which showed a potency between morphine and paracetamol. In the formalin assay, the antinociceptive activity of morphine during phase I was 122, 295 and 1695 times higher than dexketoprofen, ketoprofen and paracetamol, respectively. Isobolographic analysis demonstrated that the combination of sub-analgesic doses of dexketoprofen with morphine or with paracetamol was strongly synergic in all three tests. Synergistic drug combinations should improve effective pharmacological treatment of pain, minimizing drug specific adverse effects. These findings are undoubtedly worthy of additional controlled clinical trials in severe pain syndromes.

Idioma originalEnglish
Páginas (desde-hasta)291-296
Número de páginas6
PublicaciónNeuropharmacology
Volumen52
N.º2
DOI
EstadoPublished - 1 feb 2007

Huella dactilar

Acute Pain
Acetaminophen
Morphine
Animal Models
Ketoprofen
Pain
Formaldehyde
Tail
Controlled Clinical Trials
Drug Combinations
Acetic Acid
Analgesics
Pharmacology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Citar esto

Miranda, Hugo F. ; Puig, Margarita M. ; Dursteler, Christian ; Prieto, Juan Carlos ; Pinardi, Gianni. / Dexketoprofen-induced antinociception in animal models of acute pain : Synergy with morphine and paracetamol. En: Neuropharmacology. 2007 ; Vol. 52, N.º 2. pp. 291-296.
@article{971a647fc51542fa999d7f609922915f,
title = "Dexketoprofen-induced antinociception in animal models of acute pain: Synergy with morphine and paracetamol",
abstract = "The antinociceptive activity of dexketoprofen was studied in mice using the acetic acid writhing test (acute tonic pain), the tail flick test (acute phasic pain) and the formalin assay (inflammatory pain). Isobolographic analysis was used to study the antinociceptive interactions between morphine and paracetamol co-administered with dexketoprofen. In the writhing test, the intraperitoneal administration of dexketoprofen or ketoprofen resulted in parallel dose-response curves with equal efficacy, but higher relative potency for dexketoprofen. In the tail flick test, the curves were parallel with similar efficacy and potency. The administration of morphine or paracetamol in both tests resulted in dose-response curves not parallel with that of dexketoprofen, which showed a potency between morphine and paracetamol. In the formalin assay, the antinociceptive activity of morphine during phase I was 122, 295 and 1695 times higher than dexketoprofen, ketoprofen and paracetamol, respectively. Isobolographic analysis demonstrated that the combination of sub-analgesic doses of dexketoprofen with morphine or with paracetamol was strongly synergic in all three tests. Synergistic drug combinations should improve effective pharmacological treatment of pain, minimizing drug specific adverse effects. These findings are undoubtedly worthy of additional controlled clinical trials in severe pain syndromes.",
keywords = "Antinociception, Dexketoprofen, Formalin assay, Isobologram, Ketoprofen, Morphine, Paracetamol, Synergy, Tail flick test, Writhing test",
author = "Miranda, {Hugo F.} and Puig, {Margarita M.} and Christian Dursteler and Prieto, {Juan Carlos} and Gianni Pinardi",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.neuropharm.2006.07.025",
language = "English",
volume = "52",
pages = "291--296",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "2",

}

Dexketoprofen-induced antinociception in animal models of acute pain : Synergy with morphine and paracetamol. / Miranda, Hugo F.; Puig, Margarita M.; Dursteler, Christian; Prieto, Juan Carlos; Pinardi, Gianni.

En: Neuropharmacology, Vol. 52, N.º 2, 01.02.2007, p. 291-296.

Resultado de la investigación: Article

TY - JOUR

T1 - Dexketoprofen-induced antinociception in animal models of acute pain

T2 - Synergy with morphine and paracetamol

AU - Miranda, Hugo F.

AU - Puig, Margarita M.

AU - Dursteler, Christian

AU - Prieto, Juan Carlos

AU - Pinardi, Gianni

PY - 2007/2/1

Y1 - 2007/2/1

N2 - The antinociceptive activity of dexketoprofen was studied in mice using the acetic acid writhing test (acute tonic pain), the tail flick test (acute phasic pain) and the formalin assay (inflammatory pain). Isobolographic analysis was used to study the antinociceptive interactions between morphine and paracetamol co-administered with dexketoprofen. In the writhing test, the intraperitoneal administration of dexketoprofen or ketoprofen resulted in parallel dose-response curves with equal efficacy, but higher relative potency for dexketoprofen. In the tail flick test, the curves were parallel with similar efficacy and potency. The administration of morphine or paracetamol in both tests resulted in dose-response curves not parallel with that of dexketoprofen, which showed a potency between morphine and paracetamol. In the formalin assay, the antinociceptive activity of morphine during phase I was 122, 295 and 1695 times higher than dexketoprofen, ketoprofen and paracetamol, respectively. Isobolographic analysis demonstrated that the combination of sub-analgesic doses of dexketoprofen with morphine or with paracetamol was strongly synergic in all three tests. Synergistic drug combinations should improve effective pharmacological treatment of pain, minimizing drug specific adverse effects. These findings are undoubtedly worthy of additional controlled clinical trials in severe pain syndromes.

AB - The antinociceptive activity of dexketoprofen was studied in mice using the acetic acid writhing test (acute tonic pain), the tail flick test (acute phasic pain) and the formalin assay (inflammatory pain). Isobolographic analysis was used to study the antinociceptive interactions between morphine and paracetamol co-administered with dexketoprofen. In the writhing test, the intraperitoneal administration of dexketoprofen or ketoprofen resulted in parallel dose-response curves with equal efficacy, but higher relative potency for dexketoprofen. In the tail flick test, the curves were parallel with similar efficacy and potency. The administration of morphine or paracetamol in both tests resulted in dose-response curves not parallel with that of dexketoprofen, which showed a potency between morphine and paracetamol. In the formalin assay, the antinociceptive activity of morphine during phase I was 122, 295 and 1695 times higher than dexketoprofen, ketoprofen and paracetamol, respectively. Isobolographic analysis demonstrated that the combination of sub-analgesic doses of dexketoprofen with morphine or with paracetamol was strongly synergic in all three tests. Synergistic drug combinations should improve effective pharmacological treatment of pain, minimizing drug specific adverse effects. These findings are undoubtedly worthy of additional controlled clinical trials in severe pain syndromes.

KW - Antinociception

KW - Dexketoprofen

KW - Formalin assay

KW - Isobologram

KW - Ketoprofen

KW - Morphine

KW - Paracetamol

KW - Synergy

KW - Tail flick test

KW - Writhing test

UR - http://www.scopus.com/inward/record.url?scp=33846438213&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2006.07.025

DO - 10.1016/j.neuropharm.2006.07.025

M3 - Article

C2 - 17074372

AN - SCOPUS:33846438213

VL - 52

SP - 291

EP - 296

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 2

ER -